Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
OBJECTIVE
To analyse the acceptability and patterns of use of the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) among young European women.


METHODS
A total of 454 women aged 20-35 years opting to switch their method of contraception from oral contraception to the LNG-IUS or ENG implant, were recruited in an observational study in four different European countries (France, Ireland, Slovakia and the United Kingdom). The present paper reports the interim results of the study at 12 months of observation.


RESULTS
Data from 311 subjects (211 using the LNG-IUS and 100 using the ENG implant), with at least one follow-up visit after insertion, were analysed. The cumulative continuation rates at 12 months for the LNG-IUS and ENG implant were 93% and 86%, respectively. Most women were satisfied with their method of contraception after one year of follow-up (80% in the LNG-IUS group and 66% in the ENG implant group).


CONCLUSIONS
Both the LNG-IUS and the ENG implant are highly acceptable contraceptive options among women with previous experience of oral contraceptive use. The highest continuation and satisfaction rates were observed with the LNG-IUS.
Rock Court Medical Centre , Blackrock, Co. Dublin, Ireland. mashort@eircom.net
Mary
M
Short
Dominique
D
Dallay
Salmon
S
Omokanye
Jens Ulrich
JU
Hanisch
Pirjo
P
Inki
D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D017135:Desogestrel / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage*; D010342:Patient Acceptance of Health Care; D045167:Progesterone Congeners / Q000008:administration & dosage; D036301:Qualitative Research
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D004343:Drug Implants; D045167:Progesterone Congeners; C044815:etonogestrel; D016912:Levonorgestrel; D017135:Desogestrel